3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
10
Lung Neoplasms
4
Brain Neoplasms
3
Neoplasms
2
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Esophageal Neoplasms
1
Bronchial Neoplasms
1
Adenocarcinoma of Lung
1
Interventions
Cochlear Implants
3
Radiosurgery
2
Lapatinib
2
Everolimus
2
Bevacizumab
2
tozuleristide
1
icotinib
1
Triamcinolone Acetonide
1
Temozolomide
1
Sirolimus
1
Radiotherapy, Intensity-Modulated
1
Radiotherapy, Conformal
1
Mn-PyC3A
1
Microsurgery
1
Methylprednisolone
1
Gentamicins
1
Fluoresceins
1
Fluorescein
1
Exome
1
Endostatins
1
Axitinib
1
2,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Neuroma, Acoustic
×
icotinib
×
Clear all
NCT02934256
2021-09-09
Icotinib
Beijing Tiantan Hospital
Phase 2
Completed
10 enrolled